BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18487909)

  • 1. [GIST].
    Doi T
    Gan To Kagaku Ryoho; 2008 May; 35(5):737-9. PubMed ID: 18487909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571).
    DeMatteo RP
    Ann Surg Oncol; 2002 Nov; 9(9):831-9. PubMed ID: 12417503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
    Ahlman H; Nilsson O; Nilsson B
    Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
    [No Abstract]   [Full Text] [Related]  

  • 4. Rechallenge with imatinib in GIST: is more always RIGHT?
    Urban D; Lewin J; Collins IM; Mooi J; Jefford M
    Lancet Oncol; 2014 Jan; 15(1):e2-3. PubMed ID: 24384490
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)].
    Mac K; Wójcik M
    Postepy Hig Med Dosw (Online); 2007 Jun; 62():272-81. PubMed ID: 18542042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rechallenge of drugs in the era of targeted therapy.
    Nishida T; Doi T
    Lancet Oncol; 2013 Nov; 14(12):1143-5. PubMed ID: 24140185
    [No Abstract]   [Full Text] [Related]  

  • 7. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.
    Blay JY
    Cancer Treat Rev; 2011 Aug; 37(5):373-84. PubMed ID: 21195552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
    Murray M; Hatcher H; Jessop F; Williams D; Carroll N; Bulusu R; Judson I
    Pediatr Blood Cancer; 2008 Feb; 50(2):386-8. PubMed ID: 17729245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate in the treatment of gastrointestinal stromal tumour.
    Steinert DM; McAuliffe JC; Trent JC
    Expert Opin Pharmacother; 2005 Jan; 6(1):105-13. PubMed ID: 15709888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
    Kim TS; Cavnar MJ; Cohen NA; Sorenson EC; Greer JB; Seifert AM; Crawley MH; Green BL; Popow R; Pillarsetty N; Veach DR; Ku AT; Rossi F; Besmer P; Antonescu CR; Zeng S; Dematteo RP
    Clin Cancer Res; 2014 May; 20(9):2350-62. PubMed ID: 24583793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.
    Sleijfer S; Wiemer E; Seynaeve C; Verweij J
    Oncologist; 2007 Jun; 12(6):719-26. PubMed ID: 17602061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
    Gold JS; Dematteo RP
    Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary gastrointestinal stromal tumor of the liver treated with sequential therapy.
    Lin XK; Zhang Q; Yang WL; Shou CH; Liu XS; Sun JY; Yu JR
    World J Gastroenterol; 2015 Feb; 21(8):2573-6. PubMed ID: 25741171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of gastrointestinal stromal tumors.
    Hueman MT; Schulick RD
    Surg Clin North Am; 2008 Jun; 88(3):599-614, vii. PubMed ID: 18514701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies for treating GIST when imatinib fails.
    Boyar MS; Taub RN
    Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy of gastrointestinal stromal tumors.
    Koshenkov VP; Rodgers SE
    Curr Opin Oncol; 2012 Jul; 24(4):414-8. PubMed ID: 22572723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.